Sort   by:  
 Page size 
TranscriptomicsmRNA expression microarray of treatment naive vs. ponatinib-resistant DMS114 lung cancer cells
Transcriptional changes in consequence of in vitro resistance development of FGFR1-driven DMS114 lung cancer cells against the multikinase inhibitor ponatinib
ORGANISM(S): Homo sapiens 
2020-02-12 | E-MTAB-8773 | biostudies-arrayexpress
ProteomicsSignalling Inhibition by Ponatinib Disrupts Productive Alternative Lengthening of Telomeres (ALT)
Alternative lengthening of telomeres (ALT) supports telomere maintenance and replicative immortality in around 10-15% of cancers, thus representing a compelling target for therapy.To identify anti-cancer drugs that can be repurposed as ALT-centered therapies, we performed for a compound library scre...
ORGANISM(S): Homo sapiens (Human) 
2023-02-20 | PXD037501 | Pride
Telomeres Alt Ponatinib Sarcoma Jun 
GenomicsA personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia
Chronic myeloid leukaemia (CML) is characterised by the presence of a fusion driver oncogene, BCR-ABL1, which is a constitutive tyrosine kinase. Tyrosine kinase inhibitors (TKIs) are the central treatment strategy for CML patients and have significantly improved survival rates, but the T315I mutatio...
EGAS00001001150 | EGA
GenomicsSignalling inhibition by ponatinib disrupts alternative lengthening of telomeres (ALT)
Signalling inhibition by ponatinib disrupts alternative lengthening of telomeres (ALT)
PRJNA787207 | ENA
GenomicsProtective effects of metformin against ponatinib-induced toxicity in iPSC-derived cardiomyocytes
Protective effects of metformin against ponatinib-induced toxicity in iPSC-derived cardiomyocytes
PRJNA1374434 | ENA
GenomicsPonatinib-induced cardiotoxicity is driven by S100A8/A9-NLRP3-IL-1β signaling mediated excessive inflammation
Ponatinib-induced cardiotoxicity is driven by S100A8/A9-NLRP3-IL-1β signaling mediated excessive inflammation
PRJNA908827 | ENA
TranscriptomicsThe effect of Abl kinases,or Ponatinib challenging on breast cancer cells' global transcriptome
To gain insight into the signaling pathway(s) required for ABL1/ABL2-kinase activity or effected by Ponatinib treatment, we evaluated the consequences of single or double inactivation of ABL1/ABL2 cells, or Ponatinib treated cells on the transcriptome of breast cancer cells. To examine the consequen...
ORGANISM(S): Homo sapiens 
2018-03-01 | GSE95079 | GEO
TranscriptomicsSignalling inhibition by ponatinib disrupts alternative lengthening of telomeres (ALT)
Analyses of gene expression changes in cells treated with ponatinib (experiment 1), and in cells either lacking JUN or overexpressing JUN (experiment 2).
ORGANISM(S): Homo sapiens 
2023-01-30 | GSE190438 | GEO
TranscriptomicsPonatinib-induced cardiotoxicity is driven by S100A8/A9-NLRP3-IL-1β signaling mediated excessive inflammation
To delineate the underlying molecular mechanisms of ponatinib-induced cardiotoxicity, we used we a comorbitity cardiotoxicity mouse model (high fat-fed ApoE-/- mice) treated for two weeks with placebo/ or Ponatinib We then performed gene expression profiling analysis on left ventricular tissues from...
ORGANISM(S): Mus musculus 
2023-02-08 | GSE220121 | GEO
UnknownIntegrated Stress Response Potentiates Ponatinib-Induced Cardiotoxicity.
Not available
S-EPMC10940206 | biostudies-literature
Sort   by:  
 Page size